March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Immix Biopharma
(NASDAQ:IMMX)
Intraday
$2.9314
-0.1386
[-4.51%]
After-Hours
$2.9314
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.9314
-0.1386
[-4.51%]
At close: Mar 26
$2.9314
0
[0.00%]
After Hours: 4:19PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Immix Biopharma Stock (NASDAQ:IMMX)
Immix Biopharma Stock (NASDAQ: IMMX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 20, 2024
Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Benzinga Newsdesk
-
Mar 20, 2024, 9:52AM
Wednesday, February 21, 2024
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Benzinga Newsdesk
-
Feb 21, 2024, 9:39AM
Wednesday, February 07, 2024
Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis
Benzinga Newsdesk
-
Feb 7, 2024, 9:41AM
Tuesday, February 06, 2024
Reported Late Monday, Immix Biopharma Prices $15M Public Offering Of 5,535,055 Common Stock At $2.71/Share
Benzinga Newsdesk
-
Feb 6, 2024, 3:38AM
Monday, February 05, 2024
Immix Biopharma Shares Resume Trading
Benzinga Newsdesk
-
Feb 5, 2024, 3:39PM
Immix Biopharma Shares Halted On Circuit Breaker To The Downside, Stock Now Down -15.4%
Benzinga Newsdesk
-
Feb 5, 2024, 3:34PM
Immix Biopharma Shares Resume Trade
Benzinga Newsdesk
-
Feb 5, 2024, 3:33PM
Immix Biopharma Shares Halted On Circuit Breaker To The Downside, Stock Now Down -10.1%
Benzinga Newsdesk
-
Feb 5, 2024, 3:22PM
Immix Biopharma Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
Benzinga Newsdesk
-
Feb 5, 2024, 3:21PM
Thursday, January 25, 2024
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Jan 25, 2024, 2:52PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jan 25, 2024, 12:31PM
Wednesday, January 24, 2024
Immix Biopharma Statement On Jan. 2024 FDA Labeling Change Notification For Approved CAR-T Products
Benzinga Newsdesk
-
Jan 24, 2024, 8:37AM
Friday, December 15, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Dec 15, 2023, 12:31PM
Thursday, December 14, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Dec 14, 2023, 12:32PM
Monday, December 11, 2023
Immix Biopharma Announces 100% Overall Response Rate And 70% Complete Response; 23.7 Months Best Response Duration (Ongoing) For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis Patients At ASH 2023
Benzinga Newsdesk
-
Dec 11, 2023, 9:39AM
Tuesday, November 21, 2023
Immix Biopharma Announces FDA Approval Of IND Application For CAR-T NXC-201, Enabling U.S. Patient Dosing
Benzinga Newsdesk
-
Nov 21, 2023, 9:46AM
Friday, November 10, 2023
CFO at Immix Biopharma Acquires Company Stock Options Worth 293,000 Shares
Benzinga Insights
-
Nov 10, 2023, 10:00AM
Monday, November 06, 2023
Immix Biopharma shares are trading higher after the company announced additional NXC-201 data to be presented at the ASH meeting Dec. 9-12.
Benzinga Newsdesk
-
Nov 6, 2023, 11:57AM
Immix Biopharma Presents NXC-201 Data At 65th American Society Of Hematology Annual Meeting In 9 Relapsed/Refractory AL Amyloidosis Patients
Benzinga Newsdesk
-
Nov 6, 2023, 9:13AM
Monday, October 23, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Oct 23, 2023, 1:31PM
Monday, October 16, 2023
Immix Biopharma Completes 3rd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Benzinga Newsdesk
-
Oct 16, 2023, 9:06AM
Tuesday, October 03, 2023
Immix Biopharma Shares Halted On Circuit Breaker To The Downside, Stock Now Down -4.39%
Benzinga Newsdesk
-
Oct 3, 2023, 9:36AM
Immix Biopharma Announces Complete Response In 9th Relapsed/Refractory AL Amyloidosis Patient In NXC-201 Clinical Trial At IMS 20th Annual Meeting
Benzinga Newsdesk
-
Oct 3, 2023, 9:16AM
Monday, October 02, 2023
What's Going On With Cancer-Focused Immix Biopharma Stock Today?
Vandana Singh
-
Oct 2, 2023, 2:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Oct 2, 2023, 1:30PM
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data At The IMS 20th Annual Meeting, 95% Overall Response Rate In Multiple Myeloma
Benzinga Newsdesk
-
Oct 2, 2023, 8:07AM
Monday, September 25, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Sep 25, 2023, 5:31PM
Immix Biopharma Inc Files For Shelf Of Up To 5.2M Shares Of Common Stock By Selling Stockholder
Benzinga Newsdesk
-
Sep 25, 2023, 4:23PM
Thursday, September 21, 2023
U.S. Food And Drug Administration Approves Orphan Drug Designation For Immix Biopharma NXC-201 As A Treatment For Amyloid Light Chain Amyloidosis
Happy Mohamed
-
Sep 21, 2023, 8:55AM
Tuesday, September 19, 2023
Director of Immix Biopharma Purchased $200K In Stock
Benzinga Insights
-
Sep 19, 2023, 11:02AM
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Benzinga Newsdesk
-
Sep 19, 2023, 9:23AM
Wednesday, August 23, 2023
U.S. Food and Drug Administration Approves Orphan Drug Designation For Immix Biopharma NXC-201 As A Treatment For Multiple Myeloma
Happy Mohamed
-
Aug 23, 2023, 8:39AM
Tuesday, August 22, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Aug 22, 2023, 5:31PM
Immix Biopharma Announces $10M Private Placement With A Certain Accredited Investor For 3,241,076 Shares And Pre-Funded Warrants To Purchase 1,913,661 Shares Of Common Stock At a Price Of $1.94/Unit
Benzinga Newsdesk
-
Aug 22, 2023, 4:12PM
Wednesday, August 16, 2023
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted For Oral Presentation At The 20th International Myeloma Society Annual Meeting September 27-30 In Athens Greece
Happy Mohamed
-
Aug 16, 2023, 9:07AM
Tuesday, August 15, 2023
CFO at Immix Biopharma Acquires Company Stock Options Worth 193,000 Shares
Benzinga Insights
-
Aug 15, 2023, 11:03AM
Board Member at Immix Biopharma Acquires Company Stock Options Worth 20,000 Shares
Benzinga Insights
-
Aug 15, 2023, 11:03AM
Immix Biopharma Director Awarded $36K Worth of Stock Options
Benzinga Insights
-
Aug 15, 2023, 11:03AM
Monday, August 14, 2023
Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 10:11AM
Monday, July 17, 2023
Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Benzinga Newsdesk
-
Jul 17, 2023, 9:37AM
Monday, July 10, 2023
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Happy Mohamed
-
Jul 10, 2023, 9:47AM
Friday, July 07, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jul 7, 2023, 1:37PM
Monday, June 26, 2023
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting With FDA On NXC-201 U.S. Clinical Trial
Happy Mohamed
-
Jun 26, 2023, 9:49AM
Friday, May 26, 2023
Immix Biopharma Subsidiary Nexcella Announces Commencement Of NXC-201 Engineering Batches At Its U.S. CAR-T Manufacturing Site
Happy Mohamed
-
May 26, 2023, 9:54AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
May 26, 2023, 9:06AM
Monday, May 22, 2023
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 22, 2023, 1:20PM
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Vandana Singh
-
May 22, 2023, 11:48AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
May 22, 2023, 9:06AM
Immix Biopharma shares are trading higher after the company announced NXC-201 clinical results showed 100% overall response rate in DARZALEX-relapsed or refractory AL amyloidosis with zero ICANs in the ongoing NEXICART-1 Phase 1b/2a trial.
Benzinga Newsdesk
-
May 22, 2023, 8:19AM
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 22, 2023, 8:06AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch